Literature DB >> 17252163

Science and strategy for preventing and managing corneal ulceration.

Sonal S Tuli1, Gregory S Schultz, Donald M Downer.   

Abstract

ABSTRACT Corneal ulcers can cause significant loss of vision from scarring and astigmatism, but rapid management can limit the destruction and improve outcomes. Infectious ulcers usually resolve with antimicrobial treatment. Noninfectious ulcers, however, present a diagnostic and therapeutic challenge. They can often be resolved by eliminating toxic medications and providing surface support with lubrication and collagenase inhibitors, but resistant ulcers may need more aggressive therapy with bandage contact lenses, tarsorrhaphy, or autologous serum. Ulcers impending perforation require urgent surgical management (e.g., tissue glue, conjunctival flaps, or keratoplasty). Topical steroids are useful when the ulceration is secondary to inflammatory mediators, but they are contraindicated in corneal melts with minimal inflammation, such as those associated with Sjogren syndrome. Systemic immunomodulation is required in addition to topical therapy in the presence of autoimmune disease. Understanding of the pathological processes that occur in different types of corneal ulcers is essential to formulation of a logical and effective treatment plan. Newer, more targeted treatment modalities may offer treatment options that have greater efficacy and fewer adverse effects.

Entities:  

Mesh:

Year:  2007        PMID: 17252163     DOI: 10.1016/s1542-0124(12)70050-2

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  14 in total

1.  Topical Corticosteroids in the Management of Bacterial Keratitis.

Authors:  Sonal S Tuli
Journal:  Curr Ophthalmol Rep       Date:  2013-12

2.  Critical media attributes in E-beam sterilization of corneal tissue.

Authors:  Sina Sharifi; Hannah Sharifi; Ali Akbari; Fengyang Lei; Claes H Dohlman; Miguel Gonzalez-Andrades; Curtis Guild; Eleftherios I Paschalis; James Chodosh
Journal:  Acta Biomater       Date:  2021-10-28       Impact factor: 8.947

3.  UV cross-linking of donor corneas confers resistance to keratolysis.

Authors:  Samer N Arafat; Marie-Claude Robert; Anita N Shukla; Claes H Dohlman; James Chodosh; Joseph B Ciolino
Journal:  Cornea       Date:  2014-09       Impact factor: 2.651

Review 4.  Cellular and extracellular matrix modulation of corneal stromal opacity.

Authors:  Andre A M Torricelli; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-10-01       Impact factor: 3.467

5.  Recombinant Human MG53 Protein Protects Against Alkaline-Induced Corneal Injuries in Mice.

Authors:  Owen Guo; Brent Ju; McKinley H Shawver; Bingchuan Geng; Siqi Wei; Terriah Early; Frank Yi; Tao Tan; Heather L Chandler; Jianjie Ma; Hua Zhu
Journal:  Mil Med       Date:  2021-01-25       Impact factor: 1.437

6.  Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases.

Authors:  Ronald M Sánchez-Ávila; Edmar Uribe-Badillo; Carlos Fernández-Vega González; Francisco Muruzabal; Borja de la Sen-Corcuera; Begoña Baamonde; Luis M Quirós; Eduardo Anitua; Jesús Merayo-Lloves
Journal:  Vision (Basel)       Date:  2021-07-02

7.  Outcome of penetrating keratoplasty in corneal ulcer: a single-center experience.

Authors:  Mohammad Reza Sedghipour; Rana Sorkhabi; Abdollah Shenasi; Hassan Dehghan
Journal:  Clin Ophthalmol       Date:  2011-09-06

8.  Umbilical Cord Patch Transplantation for Corneal Perforations and Descemetoceles.

Authors:  Hua-Tao Xie; Dan Zhao; Yang Liu; Ming-Chang Zhang
Journal:  J Ophthalmol       Date:  2017-06-04       Impact factor: 1.909

9.  Amniotic membrane transplantation for infectious keratitis: a systematic review and meta-analysis.

Authors:  Darren Shu Jeng Ting; Christin Henein; Dalia G Said; Harminder S Dua
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.996

10.  Colocalization of Galectin-3 With CD147 Is Associated With Increased Gelatinolytic Activity in Ulcerating Human Corneas.

Authors:  Andrea Cruzat; Miguel Gonzalez-Andrades; Jérôme Mauris; Dina B AbuSamra; Preethi Chidambaram; Kenneth R Kenyon; James Chodosh; Claes H Dohlman; Pablo Argüeso
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.